p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer

Administration of the microtubule inhibitor docetaxel is a common treatment for metastatic castration-resistant prostate cancer (mCRPC) and results in prolonged patient overall survival. Usually, after a short period of time chemotherapy resistance emerges and there is urgent need to find new therap...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Endocr Relat Cancer
Hlavní autoři: Gruber, Martina, Ferrone, Lavinia, Puhr, Martin, Santer, Frédéric R, Furlan, Tobias, Eder, Iris E, Sampson, Natalie, Schäfer, Georg, Handle, Florian, Culig, Zoran
Médium: Artigo
Jazyk:Inglês
Vydáno: Bioscientifica Ltd 2020
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7040497/
https://ncbi.nlm.nih.gov/pubmed/31951590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-19-0488
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky